Journey Medical Future Growth
Future criteria checks 1/6
Journey Medical is forecast to grow earnings and revenue by 41.4% and 12.8% per annum respectively while EPS is expected to grow by 40.7% per annum.
Key information
41.4%
Earnings growth rate
40.7%
EPS growth rate
Pharmaceuticals earnings growth | 23.4% |
Revenue growth rate | 12.8% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 22 Mar 2024 |
Recent future growth updates
Recent updates
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 80 | -9 | N/A | N/A | 1 |
12/31/2025 | 82 | -4 | N/A | N/A | 2 |
12/31/2024 | 58 | -15 | N/A | N/A | 2 |
12/31/2023 | 79 | -4 | 0 | 5 | N/A |
9/30/2023 | 80 | -12 | 13 | 18 | N/A |
6/30/2023 | 61 | -39 | -13 | -8 | N/A |
3/31/2023 | 63 | -38 | -20 | -15 | N/A |
12/31/2022 | 74 | -30 | -34 | -14 | N/A |
9/30/2022 | 75 | -41 | -34 | -13 | N/A |
6/30/2022 | 79 | -41 | -29 | 1 | N/A |
3/31/2022 | 76 | -46 | -33 | -3 | N/A |
12/31/2021 | 63 | -44 | -12 | -2 | N/A |
9/30/2021 | 59 | -20 | -3 | 6 | N/A |
6/30/2021 | 49 | -9 | -3 | -2 | N/A |
3/31/2021 | 45 | 4 | 5 | 6 | N/A |
12/31/2020 | 45 | 5 | 4 | 5 | N/A |
12/31/2019 | 35 | 4 | 7 | 9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DERM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DERM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DERM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DERM's revenue (12.8% per year) is forecast to grow faster than the US market (8.2% per year).
High Growth Revenue: DERM's revenue (12.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DERM's Return on Equity is forecast to be high in 3 years time